We previously demonstrated that targeted inhibition of an alternate cAMP-specific phosphodiesterase, PDE4, had significant anti-brain tumor activity, when tested in a spontaneous model of low-grade glioma and in intracranial xenograft models of GBM and medulloblastoma [23], [24]. This evidence concerns the gene PDE4A and medulloblastoma.